You just read:

Neuraltus Pharmaceuticals Announces Plans for Second Phase 2 Study of NP001 in ALS Using Biomarker for Enriched Patient Selection

News provided by

Neuraltus Pharmaceuticals, Inc.

Apr 04, 2016, 08:35 ET